TY  - EJOU
AU  - FRANCOEUR, ALEX A. 
AU  - AYOUB, NATALIE 
AU  - GREENBERG, DANIELLE 
AU  - TEWARI, KRISHNANSU S. 

TI  - Drug discovery in advanced and recurrent endometrial cancer: Recent advances
T2  - Oncology Research

PY  - 2025
VL  - 33
IS  - 7
SN  - 1555-3906

AB  - 
Endometrial cancer is the most common gynecologic cancer diagnosed in the United States and mortality is on the rise. Advanced and recurrent endometrial cancer represents a treatment challenge as historically there have been limited therapeutic options for patients. In the last several years, multiple practice-changing clinical trials have led to significant improvements in the treatment landscape. This review will cover updates in the treatment and management of advanced and recurrent endometrial cancer with a focus on novel therapeutics, such as anti-PD-L1 and PD-1 inhibitors, poly ADP-ribose polymerase (PARP) inhibitors, antibody-drug conjugates, and hormonal therapy.
KW  - Advanced endometrial cancer; Recurrent endometrial cancer; Drug discovery; Tumor cancer genome atlas; Targeted therapy; Chemotherapy; immunotherapy

DO  - 10.32604/or.2025.061120